masshealth glp-1 coverage 2026 will stop covering weight-loss drugs next week As proposed MassHealth cuts threaten

In December 2024, Eli Lilly, the US pharmaceutical giant, announced the launch of its blockbuster drug, Tirzepatide, in India in 2025

PMC 4107414

Additionally, Mounjaro , one of the newer diabetes drugs, which was approved in May 2022 and has a unique dual mechanism of action (it activates the GLP-1 hormone as well as another hormone called the glucose-dependent insulinotropic polypeptide or GIP, both helping to improve blood sugar) may be even more effective than semaglutide in reducing weight

Early access

Anecdotal Reports There are anecdotal reports of vegans becoming B12-deficient after relying on multivitamins or prenatal supplements without an additional B12-only supplement

Prevalence of arthritis among adults United States, 20192021